The news is directly about AnaptysBio. The analyst's decision to maintain a Neutral rating indicates that they do not expect significant changes in the stock's performance. However, the increase in the price target from $18 to $20 suggests a positive outlook, which could potentially influence investors' decisions and the stock's price. The impact is neutral as the rating has not changed, but the raised price target could have a positive effect.